Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
300estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-22 | actual | When the study began enrolling |
| Primary completion | 2025-07-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer (NSCLC)
Interventions
- Biological: Nivolumab + ipilimumab
- Biological: Nivolumab + ipilimumab + platinum-based chemotherapy
- Biological: Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy
- Biological: Other dual-immuno-oncology therapy with chemotherapy
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-related adverse events
measured Baseline
Participant baseline clinical characteristics
measured Baseline
Time to onset of treatment-related adverse events
measured Up to 8 years
Number of treatment-related adverse events resolved
measured Up to 8 years
Number of participants receiving treatment for treatment-related adverse events by drug class
measured Up to 8 years
Number of participants that discontinued immune-oncology therapy due to treatment-related adverse events
measured Up to 8 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed